Fresenius Kabi Oncology Limited, a active public limited company, was established on 18 March 2003 in New Delhi, Delhi, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: U24231DL2003PLC119441. Registered under ROC Roc Delhi. it is unlisted. It has an authorized capital of ₹50.00 Cr and a paid-up capital of ₹48.04 Cr.
Formerly known as Dabur Pharma Limited. It upholds a compliant status. Employing 1,165 professional, Its leadership includes Nikhil Kulshreshtha (Whole-Time Director), Maximilian Alexander Bohmer (Director), Arvind Kumar Sharma (Managing Director). Past directors included Dheeraj Chopra, Dilip Girdharlal Shah, Shefali Chinmoy Khaladkar. It holds no open charges and ₹240.70 Cr settled loans. Its latest AGM occurred on 20 August 2025, with the balance sheet filed on 31 March 2025. It is based at B- 310, Som Datt Chambers - I Bhikaji Cama Place, New Delhi, Delhi, 110066.
U24231DL2003PLC119441
119441
18 March 2003
₹50.00 Cr
₹48.04 Cr
Roc Delhi
Unlisted
Active
Explore comprehensive insights into Fresenius Kabi Oncology Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Nikhil Kulshreshtha | Whole-Time Director | 20 Aug 2015 | Current |
| Maximilian Alexander Bohmer | Director | 29 Aug 2023 | Current |
| Arvind Kumar Sharma | Managing Director | 01 Jul 2018 | Current |
| Heike Susanne Van Dawen | Director | 04 Jun 2024 | Current |
| Uday Chandrashekhar Shetty | Director | 25 Nov 2020 | Current |
| Eduardo Ricardo Dos Santos Montanha | Additional Director | 15 Sep 2025 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Person Incharge | 31 May 2012 | Past |
| Pramod Abcsdd | Director | 22 Feb 2019 | Past |
| Pramod Abcsdd | Cfo(Kmp) | 31 Dec 2015 | Past |
| Pramod Abcsdd | Additional Director | 29 Jul 2009 | Past |
| Pramod Abcsdd | Whole-Time Director | 19 Aug 2015 | Past |
| Pramod Abcsdd | Additional Director | 26 Aug 2024 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Fresenius Kabi Oncology Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 7.09% increase. The company also saw a substantial improvement in profitability, with a 27.35% increase in profit. The company's net worth moved up by a moderate rise of 3.98%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Fresenius Kabi Oncology had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹0
₹2,407,000,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Sep 2008 | Idbi Bank Limited | ₹19.00 Cr | Satisfied |
| 16 Jul 2008 | Punjab National Bank | ₹15.00 Cr | Satisfied |
| 29 Sep 2006 | Hsbc Bank Plc | ₹67.00 Cr | Satisfied |
| 31 Dec 2003 | Idbi Bank Limited (Lead Bank) | ₹139.70 Cr | Satisfied |
Explore comprehensive loan charge details -
Fresenius Kabi Oncology has a workforce of 1165 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Fresenius Kabi Oncology, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Fresenius Kabi Oncology's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Eduardo Ricardo Dos Santos Montanha was appointed as a Additional Director was appointed as a Additional Director on 15 Sep 2025 & has been associated with this company since 3 months 8 days . was recorded as a recent event.
The activity Fresenius Kabi Oncology Limited last Annual general meeting of members was held on 20 Aug 2025 as per latest MCA records. was completed.
Fresenius Kabi Oncology Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Delhi. was recorded as a recent event.
Heike Susanne Van Dawen was appointed as a Director was appointed as a Director on 04 Jun 2024 & has been associated with this company since 1 year 6 months . was recorded as a recent event.
The activity Maximilian Alexander Bohmer was appointed as a Director was appointed as a Director on 29 Aug 2023 & has been associated with this company since 2 years 3 months . was completed.
The activity Rahul Sharma was appointed as a CFO was appointed as a CFO on 07 Mar 2022 & has been associated with this company since 3 years 9 months . was completed.
The CIN of Fresenius Kabi Oncology Limited is U24231DL2003PLC119441.
Fresenius Kabi Oncology Limited is headquartered at B- 310, Som Datt Chambers - I Bhikaji Cama Place, New Delhi, Delhi, 110066.
Fresenius Kabi Oncology Limited was incorporated on 18 March 2003.
The current directors of Fresenius Kabi Oncology Limited are
The primary industry of Fresenius Kabi Oncology Limited is Manufacturing.
Fresenius Kabi Oncology Limited is unlisted.
The authorized capital of Fresenius Kabi Oncology Limited is ₹50.00 Cr, and the paid-up capital is ₹48.04 Cr.
The compliance status of Fresenius Kabi Oncology Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX